Carregant...
Impact of Switching from Twice-Daily Basal Insulin to Once-Daily Insulin Glargine 300 U/mL in People with Type 1 Diabetes on Basal–Bolus Insulin: Phase 4 OPTIMIZE Study
INTRODUCTION: OPTIMIZE evaluated the efficacy, safety and treatment satisfaction of insulin glargine 300 U/mL once daily (Gla-300 OD) in people with type 1 diabetes mellitus (T1DM) previously uncontrolled on basal insulin twice daily (BID) as part of basal–bolus therapy. METHODS: OPTIMIZE was a 28-w...
Guardat en:
| Publicat a: | Diabetes Ther |
|---|---|
| Autors principals: | , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Springer Healthcare
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6995801/ https://ncbi.nlm.nih.gov/pubmed/31925722 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13300-019-00749-1 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|